S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Best Bear Market Funds: Top 3 Investment Options to Consider
Low VIX? 3 High Beta Stocks To Boost Your Returns
How and When to Roll Your Options Positions?
A UK financial trader dubbed the ringleader of an interest rate manipulation scandal loses an appeal
NASDAQ:BIOC

Biocept (BIOC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.43
$1.67
52-Week Range
N/A
Volume
751,400 shs
Average Volume
764,067 shs
Market Capitalization
$1.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
BIOC stock logo

About Biocept Stock (NASDAQ:BIOC)

Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. On October 13, 2023, Biocept, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

BIOC Stock News Headlines

Major Elon Musk Crypto Leak Revealed
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Biocept (NASDAQ: BIOC)
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Biocept Falls 46% After Chapter 7 Filing
Maxim Group Remains a Hold on Biocept (BIOC)
Biocept (BIOC) Gets a Hold from Maxim Group
Biocept Reports Second Quarter 2023 Financial Results
See More Headlines
Receive BIOC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biocept and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostics & Research
Sub-Industry
N/A
Current Symbol
NASDAQ:BIOC
Employees
50
Year Founded
1993

Profitability

Net Income
$-32,090,000.00
Pretax Margin
-564.02%

Debt

Sales & Book Value

Annual Sales
$25.86 million
Book Value
$15.60 per share

Miscellaneous

Free Float
2,584,000
Market Cap
$1.14 million
Optionable
Not Optionable
Beta
0.69

Social Links

(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Darrell Taylor Esq. (Age 58)
    Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Registered In-House Counsel
    Comp: $432.27k
  • Dr. Soon Kap Hahn Ph.D.
    Founder
  • Mr. Rob Walsh
    VP & Controller
  • Dr. Philippe J. Marchand Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Pavel Tsinberg
    Director of Technology Development
  • Mr. David S. Moskowitz R.Ph.
    MBA, Vice President of Strategy & Corporate Communications
  • Dr. Veena M. Singh (Age 48)
    Senior Medical Director
    Comp: $361.03k

BIOC Stock Analysis - Frequently Asked Questions

Should I buy or sell Biocept stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BIOC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIOC, but not buy additional shares or sell existing shares.
View BIOC analyst ratings
or view top-rated stocks.

How were Biocept's earnings last quarter?

Biocept, Inc. (NASDAQ:BIOC) posted its quarterly earnings data on Monday, November, 15th. The medical research company reported $0.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.70 by $1.80. The medical research company had revenue of $17.47 million for the quarter, compared to analyst estimates of $16.87 million. During the same quarter last year, the company earned ($12.90) earnings per share.

When did Biocept's stock split?

Biocept's stock reverse split on the morning of Wednesday, May 17th 2023. The 1-30 reverse split was announced on Wednesday, May 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What is Michael Nall's approval rating as Biocept's CEO?

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

What other stocks do shareholders of Biocept own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Who are Biocept's major shareholders?

Biocept's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

This page (NASDAQ:BIOC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners